LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09887 LEADS BIOLABS-B

Market Closed 12-05 16:09:08

51.700

-0.800

-1.52%

High52.500	Low51.400	Vol386.23K
Open52.500	D1 Closing52.500	Amplitude2.10%
Mkt Cap10.29B	Tradable Cap7.91B	Total Shares199.00M
T/O20.02M	T/O Rate0.25%	Tradable Shares153.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":51.7,"timestamp":1764922148009,"preClose":52.5,"halted":0,"volume":386231,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"Market Closed","change":-0.8,"latestTime":"12-05 16:09:08","open":52.5,"high":52.5,"low":51.4,"amount":20016412,"amplitude":0.020952,"askPrice":51.7,"askSize":18500,"bidPrice":51.4,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":52.5,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0.6510337829958496,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"1175877194","title":"Nanjing Leads Biolabs (09887) Announces November 2025 Share Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=1175877194","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175877194?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:24","pubTimestamp":1764714259,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock code: 09887) released its monthly return for the period ended 30 November 2025, submitted on 03 December 2025. According to the filing, the total authorised and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1191587742","title":"Nanjing Leads Biolabs (9887) Announces NMPA IND Approval for LBL-047 and Global Partnership with Dianthus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587742","media":"Bulletin Express","labels":["corporation","productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191587742?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:46","pubTimestamp":1764578773,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that on November 25, 2025, the National Medical Products Administration approved the Investigational New Drug application for its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1105808802","title":"LEADS BIOLABS-B (09887): LBL-047 Receives IND Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1105808802","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105808802?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:36","pubTimestamp":1764578181,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on November 25, 2025, its self-developed investigational drug LBL-047 received Investigational New Drug (IND) approval from China's National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","IND","HK0000252152.HKD","09887","BK1161"],"gpt_icon":0},{"id":"2588006747","title":"Nanjing Leads Biolabs Receives NMPA IND Approval for LBL-047","url":"https://stock-news.laohu8.com/highlight/detail?id=2588006747","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588006747?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:31","pubTimestamp":1764577861,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. announced that its self-developed drug candidate LBL-047 has received Investigational New Drug  approval from the National Medical Products Administration  of China. LBL-047 is notable for being the world's first bispecific fusion protein combining a humanized anti-BDCA2 antibody and an engineered TACI ectodomain to receive IND approval in both China and the United States. The approved clinical trial will be a double-blind, randomized, placebo-controlled study. There are currently no approved clinical trials globally targeting both plasmacytoid dendritic cells  and B cells, positioning LBL-047 as a strong first and best-in-class candidate. The approval is specific to Nanjing Leads Biolabs Co. Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4Rxp3z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2588747045","title":"Nanjing Leads Biolabs Co Ltd - Lbl-047 Receives Ind Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2588747045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588747045?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:30","pubTimestamp":1764577837,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X40QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","09887","HK0000252152.HKD"],"gpt_icon":0},{"id":"1130540191","title":"Nanjing Leads Biolabs Announces H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1130540191","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130540191?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:44","pubTimestamp":1764341044,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (\"Nanjing Leads Biolabs\") has introduced an H Share Award Scheme, formulated in accordance with relevant laws and regulations. The scheme will have a validity period...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1137190048","title":"Nanjing Leads Biolabs (9887) Announces Extraordinary General Meeting on December 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1137190048","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137190048?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:23","pubTimestamp":1764339792,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has released a proxy form for an Extraordinary General Meeting (EGM) scheduled for December 17, 2025, at 10:00 a.m. The EGM will take place on Floor...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1144181751","title":"Nanjing Leads Biolabs (9887) Announces Extraordinary General Meeting on December 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1144181751","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144181751?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:21","pubTimestamp":1764339692,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has announced that an extraordinary general meeting (EGM) will take place on December 17, 2025, at 10:00 a.m. in Nanjing, PRC. The key items on the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1165982662","title":"Nanjing Leads Biolabs (9887) Announces H Share Award Scheme, Proposes Supervisory Committee Cancellation and Articles Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=1165982662","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165982662?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:21","pubTimestamp":1764339684,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) has released a circular calling for an Extraordinary General Meeting (EGM) on December 17, 2025. The proposals up for consideration include the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2586738161","title":"Nanjing Leads Biolabs Co. Ltd. Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586738161?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:19","pubTimestamp":1764339558,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. will hold an extraordinary general meeting on December 17, 2025, in Nanjing, the People's Republic of China. During the meeting, shareholders will consider and vote on several special resolutions, including the proposed adoption of the H Share Award Scheme and the proposed authorization to the Board and/or the Delegatee to handle matters related to the H Share Award Scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDLbfPJxH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"gpt_icon":0},{"id":"1188323561","title":"Nanjing Leads Biolabs Co., Ltd. (9887) Announces Book Closure for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1188323561","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188323561?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:09","pubTimestamp":1764241786,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (stock code: 9887) has scheduled an extraordinary general meeting (EGM) on Wednesday, December 17, 2025. According to the announcement, the register of members of H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1188166925","title":"Nanjing Leads Biolabs (9887) Announces Proposed H Share Award Scheme and Supervisory Committee Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1188166925","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188166925?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:02","pubTimestamp":1764082960,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that on November 25, 2025, its board of directors approved the proposed adoption of an H Share Award Scheme, alongside the proposed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1199480251","title":"LEADS BIOLABS-B (09887) Proposes Adoption of H-Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1199480251","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199480251?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:52","pubTimestamp":1764082331,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced on November 25, 2025, that its board has approved the proposal to adopt an H-share incentive plan. The H-share incentive plan aims to: promote the company's...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"gpt_icon":0},{"id":"1101918459","title":"Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase II Trial for First-Line Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1101918459","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101918459?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:54","pubTimestamp":1762764870,"startTime":"0","endTime":"0","summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited do not accept responsibility for the contents of the original announcement, make no representation as to its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1179684957","title":"LEADS BIOLABS-B (09887): First Patient Dosed in Phase II Trial of LBL-024 as First-Line Treatment for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1179684957","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179684957?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:46","pubTimestamp":1762764384,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase II clinical study evaluating oplitelimab (PD-L1/4-1BB bispecific antibody LBL-024) as a first-line...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2582825908","title":"Nanjing Leads Biolabs Doses First Patient in Phase II Trial of LBL-024 for Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582825908","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582825908?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:41","pubTimestamp":1762764115,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. has announced the initiation of a Phase II clinical trial for Opamtistomig , a PD-L1/4-1BB bispecific antibody, as a first-line treatment for hepatocellular carcinoma. The first patient has been successfully dosed in this open-label, multi-center study, which is led by Professor Jian Zhou of Zhongshan Hospital, Fudan University, and is being conducted across multiple hospitals in China. The company previously received approval from the National Medical Products Administration for a single-arm registrational trial in April 2024, as well as Breakthrough Therapy Designation for LBL-024 in late-line advanced EP-NEC and Orphan Drug Designation from the U.S. FDA for neuroendocrine carcinoma. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL8z7m1q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1199117456","title":"HK Stock Announcement Highlights | SOFTCARE to List Tomorrow; FIH Expects Significant Improvement in Annual Financial Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1199117456","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199117456?lang=en_us&edition=fundamental","pubTime":"2025-11-09 20:04","pubTimestamp":1762689852,"startTime":"0","endTime":"0","summary":"**Key Updates**   - **SOFTCARE (02698)**: Hong Kong public offering oversubscribed by 1,813.77 times, expected to list on November 10.   - **HENGRUI PHARMA (01276)**: HRS-2430 and SHR-4610 injections...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00434","LU0359201612.USD","01276","LU1023057109.AUD","BK1167","BK1612","BK1526","LU0359201885.HKD","BK1104","BK1160","BK1191","BK1531","02038","09887","02698","LU0359202008.SGD","LU2543165471.USD","BK1161","BK1504","BK1508"],"gpt_icon":1},{"id":"1120305355","title":"Nanjing Leads Biolabs (9887) Announces Inclusion in MSCI Global Small Cap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=1120305355","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120305355?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:22","pubTimestamp":1762489365,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that its shares will be included in the MSCI Global Small Cap Indexes effective after the market close on November 24, 2025. This...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1120952844","title":"LEADS BIOLABS-B (09887) Included in MSCI Global Small Cap Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1120952844","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120952844?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:08","pubTimestamp":1762488492,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the company will be added to the MSCI Global Small Cap Index, effective after the market close on November 24, 2025. The MSCI Global Small Cap Index, compiled...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1691799644.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU1267930730.SGD","LU0109391861.USD","LU2095319765.USD","09887","LU2265009873.SGD","LU1804176565.USD","LU0672654240.SGD","MSCI","LU0320765059.SGD","LU0511384066.AUD","LU0708995401.HKD","LU0390134368.USD","BK4585","LU0289960550.SGD","LU0289961442.SGD","BK4112","BK4588","BK1161","LU0175139822.USD","LU0289739343.SGD"],"gpt_icon":0},{"id":"2581024902","title":"Nanjing Leads Biolabs Co. Ltd. to Join MSCI Global Small Cap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2581024902","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581024902?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:07","pubTimestamp":1762488429,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. will be added to the MSCI Global Small Cap Indexes after the market close on 24 November 2025. The company's inclusion reflects recognition from global investors of its operating performance and development potential.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL4D7VM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0245},{"period":"1month","weight":-0.0817},{"period":"3month","weight":-0.2143},{"period":"6month","weight":0.4771},{"period":"ytd","weight":0.4771}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.","exchange":"SEHK","name":"LEADS BIOLABS-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LEADS BIOLABS-B(09887) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LEADS BIOLABS-B,09887,LEADS BIOLABS-B股票,LEADS BIOLABS-B股票老虎,LEADS BIOLABS-B股票老虎国际,LEADS BIOLABS-B行情,LEADS BIOLABS-B股票行情,LEADS BIOLABS-B股价,LEADS BIOLABS-B股市,LEADS BIOLABS-B股票价格,LEADS BIOLABS-B股票交易,LEADS BIOLABS-B股票购买,LEADS BIOLABS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LEADS BIOLABS-B(09887) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}